Orthofix Medical (OFIX) to Release Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) is projected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Orthofix Medical to post earnings of $0.44 per share and revenue of $218.7150 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Orthofix Medical Trading Up 0.7%

Shares of NASDAQ OFIX opened at $13.87 on Friday. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $20.48. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47. The company has a market cap of $549.25 million, a price-to-earnings ratio of -4.58 and a beta of 0.78. The business’s 50 day moving average price is $14.31 and its 200-day moving average price is $14.70.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Barrington Research reissued an “outperform” rating and set a $18.00 target price on shares of Orthofix Medical in a research report on Tuesday, February 17th. Stifel Nicolaus started coverage on shares of Orthofix Medical in a research note on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Finally, TD Cowen assumed coverage on Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 target price for the company. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.00.

Insider Buying and Selling at Orthofix Medical

In related news, CEO Massimo Calafiore sold 9,797 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the transaction, the chief executive officer owned 217,237 shares of the company’s stock, valued at $3,304,174.77. This trade represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Julie Andrews sold 4,873 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the completion of the sale, the chief financial officer directly owned 58,039 shares in the company, valued at approximately $834,600.82. The trade was a 7.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 24,270 shares of company stock worth $370,958. 1.30% of the stock is owned by insiders.

Institutional Trading of Orthofix Medical

A number of hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new position in Orthofix Medical during the fourth quarter valued at approximately $56,000. Strs Ohio acquired a new stake in shares of Orthofix Medical during the 1st quarter worth approximately $150,000. Mackenzie Financial Corp purchased a new position in shares of Orthofix Medical during the 3rd quarter valued at approximately $148,000. VARCOV Co. purchased a new position in shares of Orthofix Medical during the 4th quarter valued at approximately $164,000. Finally, Creative Planning acquired a new position in shares of Orthofix Medical in the 3rd quarter valued at $172,000. Hedge funds and other institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.